AMAG Pharmaceuticals (AMAG) Earning Somewhat Favorable Media Coverage, Accern Reports
News headlines about AMAG Pharmaceuticals (NASDAQ:AMAG) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. AMAG Pharmaceuticals earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave news stories about the specialty pharmaceutical company an impact score of 45.7156279209 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the media headlines that may have effected Accern’s rankings:
- Oral Mucositis Market Accretes Dramatically With A Whooping CAGR of ~7% by 2023; Confirms MRFR (medgadget.com)
- CA 125 Test Market 2017 Global Industry Overview and Competitive Analysis Research Report To 2022 (medgadget.com)
- AMAG Pharmaceuticals, Inc. (AMAG) – Hot Healthcare stock Alert – Nasdaq Fortune (press release) (nasdaqfortune.com)
- Hot Stocks: SPI Energy Co., Ltd., (NASDAQ: SPI), AMAG Pharmaceuticals, Inc., (NASDAQ: AMAG), Essent Group Ltd … – Stocks In The News (press release) (tradingnewsnow.com)
- ETFs with exposure to AMAG Pharmaceuticals, Inc. : December 12, 2017 (finance.yahoo.com)
A number of equities research analysts have commented on the company. Zacks Investment Research raised AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 target price for the company in a report on Wednesday, October 4th. Morgan Stanley assumed coverage on AMAG Pharmaceuticals in a report on Friday, September 8th. They issued an “overweight” rating and a $26.00 target price for the company. Cantor Fitzgerald reissued a “hold” rating and issued a $21.00 target price on shares of AMAG Pharmaceuticals in a report on Thursday, September 28th. Janney Montgomery Scott reissued a “hold” rating on shares of AMAG Pharmaceuticals in a report on Tuesday, October 17th. Finally, Deutsche Bank reissued a “hold” rating and issued a $24.00 target price on shares of AMAG Pharmaceuticals in a report on Thursday, August 31st. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $23.38.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.